VIN-Julie Schwartzbard

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease6 trials
• Frontotemporal dementia1 trial
• Osteoarthritis1 trial

Phase

• Phase 35 trials
• Phase 22 trials

Status

• Active, not recruiting3 trials
• Completed3 trials
• Recruiting1 trial

Lead sponsor

• Eli Lilly and Company6 trials
• Bristol-Myers Squibb1 trial

Running trials

• Recruiting

  A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

  NCT06976216· Phase 3· Bristol-Myers Squibb· Source

  Contact: Julie Schwartzbard, Site 0128

• Active, not recruiting

  A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

  NCT05738486· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

  NCT05026866· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

  NCT04437511· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease1 recruiting

Closed trials

• Completed

  A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

  NCT05463731· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease

  NCT05063539· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain

  NCT05986292· Phase 2· Eli Lilly and Company· Source